Skip to main content
Premium Trial:

Request an Annual Quote

Roche Gets CE Mark for Mutation Profiler Software for NGS Cancer Tests

NEW YORK (GenomeWeb) – Roche said today that it has received the CE mark for its Navify Mutation Profiler clinical software, which it launched today.

The software provides annotation, interpretation, and clinical reporting of next-generation sequencing tests for cancer. Along with it, Roche launched Navify Therapy Matcher, an optional clinical decision support app that helps clinicians link clinically actionable mutations to therapy options.

The two products "offer a clinical decision support solution that addresses a major workflow challenge for NGS labs, synthesizing large amounts of medical and scientific data into actionable insights," said Neil Gunn, head of Roche Sequencing Solutions, in a statement.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.